Pasithea Therapeutics Corp. Form 8-K Summary
Business Context and Reporting Period
Pasithea Therapeutics Corp. filed a Form 8-K dated January 17, 2024, with the report signed on January 18, 2024. The filing reports an exchange-listing compliance matter under Item 8.01, Other Events.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes Versus the Prior Comparable Period
Nasdaq notified the company on January 17, 2024 that its common stock had maintained a closing bid price of at least $1.00 per share for the required consecutive business days. The company therefore regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter was closed.
The compliance process followed an initial Nasdaq notice dated January 19, 2023 and a July 19, 2023 extension that provided until January 15, 2024 to regain compliance.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The principal disclosed risk was the previously identified minimum-bid-price deficiency, which has been resolved according to Nasdaq's January 17, 2024 letter.
Important Facts for Investors to Verify
- Confirm the effective date and terms of Nasdaq's closure of the minimum-bid-price deficiency.
- Monitor whether the company maintains compliance with Nasdaq's continued-listing requirements.
- Review subsequent filings for financial results, cash resources, financing activity, and additional corporate or listing risks, none of which are addressed in this filing.